The Brazilian health regulatory agency, Anvisa, has intensified its crackdown on the unregulated market for weight-loss medications, issuing urgent warnings and seizing thousands of illicit products. This surge in regulatory action comes as health officials grapple with a dangerous trend of illegally imported, falsified and improperly compounded “weight-loss pens” that bypass critical safety protocols.
Whereas GLP-1 receptor agonists—such as tirzepatide and semaglutide—have revolutionized the treatment of obesity and type 2 diabetes, their popularity has fueled a shadow market. From “Paraguayan Mounjaro” to experimental substances sold via the internet, the proliferation of unregistered medications has led to severe health complications, prompting Anvisa to move beyond simple warnings to aggressive enforcement and public health alerts.
The current crisis is not a reflection of the approved medications themselves, but rather a failure of the supply chain and a rise in consumer misuse. By targeting the distribution of adulterated drugs and clarifying the legal status of registered treatments, Anvisa aims to protect millions of patients from life-threatening side effects associated with non-clinical usage.
Urgent Health Alert: The Risk of Pancreatitis
On February 9, 2026, Anvisa issued a critical alert regarding the leverage of weight-loss pens without professional medical supervision Anvisa alert on weight-loss pens. The agency warned that these medications—including those containing semaglutide, liraglutide, tirzepatida, and dulaglutida—must be used strictly according to the approved package inserts and only under the prescription of a licensed healthcare provider.
The alert was triggered by a spike in notifications of pancreatitis, a severe inflammation of the pancreas that can disrupt digestion and blood sugar control. According to official reports, Brazil is currently investigating six deaths linked to pancreatitis associated with the use of these medications, along with more than 200 cases of pancreatic complications pancreatitis cases in Brazil. While pancreatitis is already listed as a potential adverse reaction in the medications’ inserts, the recent volume of cases has raised significant alarms.
This trend is not isolated to Brazil. The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has reported 19 deaths associated with the use of similar weight-loss pens, including cases of fatal necrotizing pancreatitis UK MHRA findings. These cases are considered rare but grave, underscoring the danger of using potent metabolic drugs without rigorous medical screening, and monitoring.
The War on Falsified Mounjaro and “Paraguayan” Imports
Parallel to the health alerts, Anvisa has launched a series of operations to purge the market of counterfeit drugs. On April 3, 2026, the agency announced the seizure of three falsified lots of Mounjaro, the tirzepatide-based medication produced by Eli Lilly Mounjaro falsified lots seizure. The operation resulted in the seizure of 23,000 irregular vials in the state of Santa Catarina Santa Catarina seizure totals.
The falsified products were identified through several critical discrepancies. Anvisa noted that the serial numbers on the seized pens were not present in the manufacturer’s official systems, the packaging materials differed from the originals, and the 2D codes failed to read correctly falsification markers. The specific adulterated lots identified by the agency are:
- Mounjaro: Lot D856831
- Mounjaro KwikPen (multidose): Lots D880730 and D840678
Beyond blatant counterfeits, Anvisa is too targeting “Mounjaro paraguaio”—products imported illegally from neighboring countries—and large-scale compounded versions of these drugs. Compounding these specific medications in pharmacies is a practice not permitted by the agency due to the inability to guarantee stability, dosage accuracy, and sterility.
Clarifying the Status of Approved Medications
Amidst the wave of seizures and alerts, there has been significant public confusion regarding whether Mounjaro itself has been banned. Anvisa has clarified that Mounjaro is not prohibited in Brazil Mounjaro registration status. The medication has held a valid registration since September 2023 and has passed all necessary safety evaluations for the treatment of type 2 diabetes and obesity.
The agency’s restrictive measures are aimed exclusively at irregular products. This includes medications produced in compounding pharmacies without authorization or products containing unapproved substances. For example, Anvisa has banned the import, sale, and use of several “weight-loss pens” that contain retatrutide, an experimental substance not approved for public use. Specific banned products include:
- T.G. 5
- Lipoless
- Tirzazep
These products are frequently marketed online with promises of rapid weight loss but lack scientific proof of efficacy and quality control, posing a severe risk to users banned retatrutide products.
What This Means for Patients and Consumers
The current regulatory environment serves as a stark reminder that metabolic medications are not cosmetic tools, but powerful pharmacological agents. The risks associated with irregular weight-loss pens in Brazil include not only the potential for ineffective treatment but also the risk of receiving adulterated substances that can lead to permanent organ damage or death.
For those seeking obesity or diabetes treatment, the only safe path is through a licensed medical professional. This ensures that the patient’s medical history is screened for contraindications—such as a history of pancreatitis—and that the medication is sourced from a registered pharmacy with a verified supply chain.
| Feature | Approved Medications (e.g., Mounjaro, Ozempic) | Irregular/Falsified Products |
|---|---|---|
| Anvisa Status | Registered and Approved | Banned or Unregistered |
| Sourcing | Certified Pharmacies | Internet, Illegal Imports, Unlicensed Compounding |
| Safety Control | Strict Manufacturer Quality Control | None; potential for contamination/wrong dose |
| Medical Requirement | Mandatory Prescription & Supervision | Often sold without medical oversight |
| Key Risks | Known side effects (listed in insert) | Unknown substances, falsified lots, severe toxicity |
Next Steps in Regulatory Enforcement
Anvisa continues to monitor the market and collaborate with law enforcement to identify and shut down illegal distribution networks. The agency has emphasized that it will continue to publish resolutions in the Official Gazette (DOU) to alert the public about newly identified falsified lots and banned substances.
Patients who suspect they have purchased a falsified medication or are experiencing severe abdominal pain—a hallmark symptom of pancreatitis—should seek immediate medical attention and report the product to Anvisa’s surveillance systems.
World Today Journal will continue to monitor Anvisa’s official publications for further updates on seized lots and new safety mandates. We encourage readers to share this information to prevent the use of dangerous, unregistered medications.